References
- de la Fuente-Fernandez R, Lidstone S, Stoessl AJ. Placebo effect and dopamine release. J Neural Transm Suppl. 2006;70:415–418.
- Pollo A, Benedetti F. The placebo response: neurobiological and clinical issues of neurological relevance. Prog Brain Res. 2009;175:283–294.
- Benedetti F, Colloca L, Torre E, et al. Placebo-responsive Parkinson patients show decreased activity in single neurons of subthalamic nucleus. Nat Neurosci. 2004;7:587–588.
- Benedetti F. Placebo effects. 2nd ed. Oxford University: Oxford University Press; 2014. p. 44.
- Paradis E, Sutkin G. Beyond a good story: from Hawthorne effect to reactivity in health professions education research. Med Educ. 2017;51:31–39.
- McCambridge J, Witton J, Elbourne DR. Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects. J Clin Epidemiol. 2014;67:267–277.
- Benedetti F, Carlino E, Piedimonte A. Increasing uncertainty in CNS clinical trials: the role of placebo, nocebo, and Hawthorne effects. Lancet Neurol. 2016;15:736–747.
- Cizza G, Piaggi P, Rother KI, et al. Hawthorne effect with transient behavioral and biochemical changes in a randomized controlled sleep extension trial of chronically short-sleeping obese adults: implications for the design and interpretation of clinical studies. PLoS One. 2014;9:e104176.
- Morberg BM, Malling AS, Jensen BR, et al. Parkinson’s disease and transcranial pulsed electromagnetic fields: a randomized clinical trial. Mov Disord. 2017;32:625–626.
- Bech P, Gefke M, Lunde M, et al. The pharmacopsychometric triangle to illustrate the effectiveness of T-PEMF concomitant with antidepressants in treatment resistant patients: a double-blind, randomised, sham-controlled trial revisited with focus on the patient-reported outcomes. Depress Res Treat. 2011;2011:806298.
- Topp CW, Ostergaard SD, Sondergaard S, et al. The WHO-5 Well-Being Index: a systematic review of the literature. Psychother Psychosom. 2015;84:167–176.
- Schneider CB, Pilhatsch M, Rifati M, et al. Utility of the WHO-Five Well-being Index as a screening tool for depression in Parkinson's disease. Mov Disord. 2010;25:777–783.
- Martinez-Martin P, Fontan C, Frades Payo B, et al. Parkinson’s disease: quantification of disability based on the Unified Parkinson's Disease Rating Scale. Neurologia. 2000;15:382–387.
- Scanlon BK, Katzen HL, Levin BE, et al. A formula for the conversion of UPDRS-III scores to Hoehn and Yahr stage. Parkinsonism Relat Disord. 2008;14:379–380.
- Martinez-Martin P, Gil-Nagel A, Gracia LM, The Cooperative Multicentric Group, et al. Unified Parkinson’s Disease Rating Scale characteristics and structure. Mov Disord. 1994;9:76–83.
- Ulrik L, Rahbek KT, Steen D. Interactions of low-frequency, pulsed electromagnetic fields with living tissue: biocehmical responses and clinical results. Oral Biosci Med. 2005;2:1–12.
- Nordenskjold A, Martensson B, Pettersson A, et al. Effects of Hesel-coil deep transcranial magnetic stimulation for depression – a systematic review. Nord J Psychiatry. 2016;70:492–497.
- Peto V, Jenkinson C, Fitzpatrick R. PDQ-39: a review of the development, validation and application of a Parkinson’s disease quality of life questionnaire and its associated measures. J Neurol. 1998;245(Suppl 1):S10–S14.
- Morberg BM, Malling AS, Jensen BR. The effects of transcranial pulsed electromagnetic field stimulation on quality of life in Parkinson’s disease. Eur J Neurol. 2018. [Epub ahead of print].
- Speer DC. Mental evaluation outcome evaluations. San Diego: Academic Press; 1998.
- Bech P, Austin S, Lau ME. Patient Reported Outcome Measures (PROMs): examination of the psychometric properties of two measures for burden of symptoms and quality of life in patients with depression or anxiety. Nord J Psychiatry. 2018. [Epub ahead of print]